IL160969A0 - Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline - Google Patents

Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Info

Publication number
IL160969A0
IL160969A0 IL16096902A IL16096902A IL160969A0 IL 160969 A0 IL160969 A0 IL 160969A0 IL 16096902 A IL16096902 A IL 16096902A IL 16096902 A IL16096902 A IL 16096902A IL 160969 A0 IL160969 A0 IL 160969A0
Authority
IL
Israel
Prior art keywords
tetrahydroisoquinol
methanesulfonamido
quinazoline
dimethoxy
pyridyl
Prior art date
Application number
IL16096902A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL160969A0 publication Critical patent/IL160969A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16096902A 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline IL160969A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations
PCT/IB2002/004040 WO2003032956A1 (en) 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Publications (1)

Publication Number Publication Date
IL160969A0 true IL160969A0 (en) 2004-08-31

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16096902A IL160969A0 (en) 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Country Status (33)

Country Link
EP (1) EP1434570B8 (de)
JP (1) JP4131471B2 (de)
KR (1) KR20050032510A (de)
CN (1) CN1568180A (de)
AP (1) AP2004003001A0 (de)
AR (1) AR036782A1 (de)
AT (1) ATE303135T1 (de)
BR (1) BR0213196A (de)
CA (1) CA2461168A1 (de)
CO (1) CO5560534A2 (de)
DE (1) DE60205925T2 (de)
DK (1) DK1434570T3 (de)
DO (1) DOP2002000464A (de)
EA (1) EA006168B1 (de)
ES (1) ES2246017T3 (de)
GB (1) GB0124455D0 (de)
GT (1) GT200200184A (de)
HR (1) HRP20040261A2 (de)
HU (1) HUP0600064A3 (de)
IL (1) IL160969A0 (de)
IS (1) IS7179A (de)
MA (1) MA27075A1 (de)
MX (1) MXPA04003293A (de)
NO (1) NO20041520L (de)
OA (1) OA12709A (de)
PA (1) PA8556001A1 (de)
PE (1) PE20030551A1 (de)
PL (1) PL369666A1 (de)
PY (1) PY0223360A (de)
SV (1) SV2004001279A (de)
UY (1) UY27477A1 (de)
WO (1) WO2003032956A1 (de)
ZA (1) ZA200401976B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053120T3 (es) * 1990-07-02 1994-07-16 Bend Res Inc Perlas microporosas asimetricas para liberacion controlada.
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
IL150634A0 (en) * 2000-03-03 2003-02-12 Pfizer 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs

Also Published As

Publication number Publication date
DOP2002000464A (es) 2003-04-15
UY27477A1 (es) 2003-05-30
PE20030551A1 (es) 2003-06-26
AP2004003001A0 (en) 2004-03-31
IS7179A (is) 2004-03-11
ATE303135T1 (de) 2005-09-15
GB0124455D0 (en) 2001-12-05
CA2461168A1 (en) 2003-04-24
JP4131471B2 (ja) 2008-08-13
GT200200184A (es) 2003-05-23
ES2246017T3 (es) 2006-02-01
MXPA04003293A (es) 2004-07-23
KR20050032510A (ko) 2005-04-07
EP1434570B1 (de) 2005-08-31
EP1434570A1 (de) 2004-07-07
DE60205925T2 (de) 2006-06-08
JP2005507909A (ja) 2005-03-24
WO2003032956A1 (en) 2003-04-24
MA27075A1 (fr) 2004-12-20
BR0213196A (pt) 2004-08-31
HUP0600064A2 (en) 2006-06-28
DE60205925D1 (de) 2005-10-06
PL369666A1 (en) 2005-05-02
ZA200401976B (en) 2004-07-12
HUP0600064A3 (en) 2007-02-28
EA006168B1 (ru) 2005-10-27
SV2004001279A (es) 2004-02-19
NO20041520L (no) 2004-04-05
CO5560534A2 (es) 2005-09-30
HRP20040261A2 (en) 2004-08-31
CN1568180A (zh) 2005-01-19
DK1434570T3 (da) 2005-11-07
EA200400431A1 (ru) 2004-08-26
OA12709A (en) 2006-06-26
AR036782A1 (es) 2004-10-06
EP1434570B8 (de) 2005-10-26
PA8556001A1 (es) 2003-07-28
PY0223360A (es) 2004-04-01

Similar Documents

Publication Publication Date Title
EE05107B1 (et) Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine
MXPA03006121A (es) Terapia de combinacion usando inhibidores del receptor tirosin-cinasa e inhibidores de la angiogenesis.
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
EG24684A (en) HIV replication inhibiting pyrimidines
AU2002238042A1 (en) Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
DK1341774T3 (da) Kondenserede heteroaromatiske glucokinase-aktivatorer
MXPA03008690A (es) Inhibidores novedosos de tirosina cinasa.
IL160714A0 (en) Heterocyclic substituted 2-(4-phenoxy) pyridine derivatives and pharmaceutical compositions containing the same
HUP0400708A3 (en) Substituted 1,3,5-triazine and pyrimidine derivatives, their use and pharmaceutical compositions containing them
AU2002313249A1 (en) Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
AU2001241927A1 (en) Inhibitors of p38-alpha kinase
DK1480983T3 (da) Heteroarylsubstituerede 2-pyridinyl- og 2-pyrimidinyl- 6,7,8,9-tetrahydropyrimido[1,2a]pyrimidin-4-onderivater
IL157442A0 (en) Cyano substituted dihydropyrimidine derivatives
MXPA03004136A (es) Derivados de pirimidina y su uso como ligandos del receptor de neuropeptido y (npy).
HUP0300006A3 (en) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs, process for their preparation and pharmaceutical compositions containing them
DK1458386T3 (da) Aroylpyrrolheteroaryl- og methanolforbindelser til behandling af en lidelse i centralnervesystemet
MXPA03001484A (es) Quinazolinas, medicamentos que contienen estos compuestos, y son efectivos como inhbidores de tirosina quinasa, su utilizacion y metodos para su produccion.
IL160969A0 (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline
MXPA03007624A (es) Procedimiento para la preparacion de (e)-5-(2-bromovinil)-2-desoxiuridina.
MXPA03003348A (es) Nuevos derivados de cianoaril (o-cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
ZA200304436B (en) Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronatry artery disease or atherosclerosis.
AU2002342833A1 (en) 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
HK1062439A (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
AU2002256260A1 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
MXPA03008588A (es) Nuevos derivados de pirimidin-2,4,6-triona, procedimiento para su produccion y agentes farmaceuticos que contienen estos compuestos.